Following the "One Health Model" to Disrupt Canine Oncology
Dogs and humans get the same types of diseases, and they are good models for one another. The cancers listed below—Osteosarcoma, B-cell Lymphoma, Melanoma, Glioblastoma—both afflict pets and their people, and have current clinical trials in humans. As we build CAR-T first for lymphoma, we envision expanding our pipeline into this list of high-value, unmet need, and translational cancers in pets.
B-cell Lymphoma
Genetic Drivers: NF-κB activation; MYC & BCL2 deregulation.
Antigens: CD19, CD20 (shared in canine & human).
CAR-T Trials: NCT02348216 (CD19-CAR T, ~80% response, Phase 2); NCT04245839 (CD20-CAR T, Phase 1).
Osteosarcoma
Genetic Drivers: TP53, RB loss; PI3K mutations (e.g., PIK3CA).
Antigens: HER2 (~40% in canine, some human OS); GD2.
CAR-T Trials: NCT03721068 (GD2-CAR T, Phase 1); NCT00902044 (HER2-CAR T, Phase 1).
Melanoma
Genetic Drivers: BRAF^V600E, NRAS in humans; MAPK upregulation in both.
Antigens: CSPG4 (>90% human, also canine); IL13Rα2.
CAR-T Trials: NCT04119024 (IL13Rα2-CAR T, Phase 1); NCT02850536 (CSPG4-CAR T, Phase 1).
Glioblastoma
Genetic Drivers: TP53, PDGF/EGFR activation; low mutation rates.
Antigens: IL13Rα2, EGFRvIII (human GBM, some canine); HER2 (subset).
CAR-T Trials: NCT02208362 (IL13Rα2-CAR T, Phase 1); NCT03726515 (EGFRvIII-CAR T + PD-1, Phase 1).